Literature DB >> 6130527

Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin.

I F James, C Chavkin, A Goldstein.   

Abstract

Opioid receptors on guinea pig brain membranes were alkylated by the naltrexone analogue beta-chlornaltrexamine. Binding of the prototypical mu and kappa ligands, [3H]dihydromorphine and [3H]ethylketocyclazocine, was more readily affected by the reagent than was binding of the delta ligand, 3H-labeled [D-Ala2, D-Leu5]enkephalin. Treatment of membranes with beta-chlornaltrexamine in the presence of dynorphin resulted in significant protection of [3H]ethylketocyclazocine binding sites, without protection of [3H]dihydromorphine or 3H-labeled [D-Ala2, D-Leu5]enkephalin sites. Similarly, [D-Ala2, D-Leu5]enkephalin and sufentanil selectively protected binding sites for 3H-labeled [D-Ala2, D-Leu5]enkephalin and [3H]dihydromorphine, respectively. Scatchard analysis of [3H]ethylketocyclazocine binding to untreated membranes suggested two types of binding site with 40-fold difference in affinities. Membranes treated with beta-chlornaltrexamine in the presence of dynorphin retained about 40% of the high-affinity sites and lost the low-affinity sites. Selective protection of sites with high affinity for dynorphin and ethylketocyclazocine was confirmed in competition binding assays. These results strongly suggest that the three types of opioid receptor are not interconvertible and provide further evidence that the endogenous peptide dynorphin is a highly selective ligand of the kappa opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130527      PMCID: PMC347382          DOI: 10.1073/pnas.79.23.7570

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Multiple opiate receptors. Enkephalins and morphine bind to receptors of different specificity.

Authors:  K J Chang; P Cuatrecasas
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

2.  Interaction of enkephalin with opiate receptors in intact cultured cells.

Authors:  K J Chang; R J Miller; P Cuatrecasas
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

3.  Problems associated with analysis and interpretation of small molecule/macromolecule binding data.

Authors:  T W Plumbridge; L J Aarons; J R Brown
Journal:  J Pharm Pharmacol       Date:  1978-02       Impact factor: 3.765

4.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

5.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.

Authors:  P S Portoghese; D L Larson; J B Jiang; T P Caruso; A E Takemori
Journal:  J Med Chem       Date:  1979-02       Impact factor: 7.446

7.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Specific protection of the binding sites of D-Ala2-D-Leu5-enkephalin (delta-receptors) and dihydromorphine (mu-receptors).

Authors:  L E Robson; H W Kosterlitz
Journal:  Proc R Soc Lond B Biol Sci       Date:  1979-08-31

10.  Rat vas deferens: a specific bioassay for endogenous opioid peptides.

Authors:  S Lemaire; J Magnan; D Regoli
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

View more
  7 in total

1.  "DAKLI": a multipurpose ligand with high affinity and selectivity for dynorphin (kappa opioid) binding sites.

Authors:  A Goldstein; J J Nestor; A Naidu; S R Newman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

2.  Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus.

Authors:  C Chavkin; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

3.  Solubilization and characterization of mu, delta, and kappa opioid binding sites from guinea pig brain: physical separation of kappa receptors.

Authors:  Y Itzhak; J M Hiller; E J Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance.

Authors:  Jay P McLaughlin; Lisa C Myers; Paul E Zarek; Marc G Caron; Robert J Lefkowitz; Traci A Czyzyk; John E Pintar; Charles Chavkin
Journal:  J Biol Chem       Date:  2003-11-03       Impact factor: 5.157

5.  kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat.

Authors:  G E Leighton; R E Rodriguez; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

6.  Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors.

Authors:  R S Zukin; M Eghbali; D Olive; E M Unterwald; A Tempel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Morphine-like discriminative stimulus effects of opioid peptides: possible modulatory role of D-Ala2-D-Leu5-enkephalin (DADL) and dynorphin A (1-13).

Authors:  M Ukai; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.